Novartis reviews FMI’s research portfolio every year and has first right of refusal on any intellectual property. But FMI and its researchers set their own agenda, says molecular geneticist, Antoine Peters. Peters is planning a project with researchers at theUniversity Hospital Baseland other Swiss...